
Baker Botts, L.L.P. announced the promotion of 14 lawyers to partner, effective January 1, 2020, including antitrust partner Jeffrey Oliver.
Jeffrey Oliver is an antitrust lawyer with an emphasis on US and international merger reviews. Jeffrey has obtained antitrust clearance for transactions in a wide variety of industries and jurisdictions, including oil and gas, heavy industry, utilities, chemicals, media, transportation, and trade associations. His global practice routinely involves substantive advocacy in the US, China, Germany, Austria, Australia, before the European Commission, and in other jurisdictions.
Prior to joining Baker Botts, Mr. Oliver was a Staff Attorney at the Federal Trade Commission (FTC), Bureau of Competition, focusing on merger and conduct investigations in the oil and gas industry. He has experience in all phases of the FTC and DOJ investigation processes, from reviewing HSR filings to challenging mergers in litigation.
“These new partners are future owners and leaders of our Firm,” said John Martin, Managing Partner of Baker Botts. “They provide exemplary client service and share in our culture of collaborative entrepreneurship, creating opportunities with and for others. They make a wide range of contributions to the Firm, not only to their clients and their colleagues, but also in their respective communities.”
Full Content: Baker Botts
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas